眼科

订阅

MedSci主页 / 所有栏目 / 眼科

Eur J Ophthalmol：老花眼矫正手术中小切口微透镜提取（SMILE）单眼视力检查！

2017-12-08 cuiguizhong MedSci原创

老花眼单眼视力屈光矫正
关注

德国慕尼黑路德维希 - 马克西米利安大学眼科医院的Luft N近日在Eur J Ophthalmol发表了他们的一项工作，他们在老花眼人群中研究了近视小切口微透镜提取（SMILE）单眼视力的结果。

德国慕尼黑路德维希 - 马克西米利安大学眼科医院的Luft N近日在Eur J Ophthalmol发表了他们的一项工作，他们在老花眼人群中研究了近视小切口微透镜提取（SMILE）单眼视力的结果。

他们的这项研究包括49位45岁以上的老花眼病人。这些患者都是在奥地利林茨的SMILE眼科诊所接受双眼SMILE和准备进行单眼视力检查，寻求手术矫正近视或近视散光。眼睛的目标折射是（远近）眼睛的平均值，范围介于-1.25和-0.50D之间。在平均术后时间7.2±4.8个月后，评估最佳矫正远视力、未矫正远视力（UDVA）、未矫正近视力以及对眼镜的依赖性。


研究群体的平均年龄为49±3岁，女性与男性的比例为30:19。在80％的患者中，距离眼睛获得了与目标屈光度±0.50D的等效球镜矫正，96％在±1.0D之内。达到20/20或更高的双眼UDVA达到90％，所有患者达到20/25或更好。双眼UDVA为20/20或更高的患者阅读J2或更好的比例达84％。 84％的患者获得了独立的眼镜独立性，92％的患者获得独立眼镜的独立性。没有病人要求进行屈光增强。

因此，他们认为，这是首次报道的SMILE 单眼视力评估研究。对于寻找屈光手术的近视患者，这种方法是矫正老花眼的安全有效的方法。

原文出处：

Luft, N., et al. Small incision lenticule extraction (SMILE) monovision for presbyopia correction. Eur J Ophthalmol, 2017: p. 0.

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1926674, encodeId=7a3019266e4df, content=<a href='/topic/show?id=1099802e804' target=_blank style='color:#2F92EE;'>#老花眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80278, encryptionId=1099802e804, topicName=老花眼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Dec 29 15:15:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541306, encodeId=f3c3154130656, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Dec 09 15:15:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267784, encodeId=03da26e784bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 08 09:02:19 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267777, encodeId=971c26e777a8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 08 08:58:39 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-29 doctorzheng

    #老花眼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1926674, encodeId=7a3019266e4df, content=<a href='/topic/show?id=1099802e804' target=_blank style='color:#2F92EE;'>#老花眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80278, encryptionId=1099802e804, topicName=老花眼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Dec 29 15:15:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541306, encodeId=f3c3154130656, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Dec 09 15:15:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267784, encodeId=03da26e784bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 08 09:02:19 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267777, encodeId=971c26e777a8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 08 08:58:39 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-09 1249842em13(暂无昵称)

    #THA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1926674, encodeId=7a3019266e4df, content=<a href='/topic/show?id=1099802e804' target=_blank style='color:#2F92EE;'>#老花眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80278, encryptionId=1099802e804, topicName=老花眼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Dec 29 15:15:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541306, encodeId=f3c3154130656, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Dec 09 15:15:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267784, encodeId=03da26e784bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 08 09:02:19 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267777, encodeId=971c26e777a8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 08 08:58:39 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-08 1ddf0692m34(暂无匿称)

    学习了.涨知识

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1926674, encodeId=7a3019266e4df, content=<a href='/topic/show?id=1099802e804' target=_blank style='color:#2F92EE;'>#老花眼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80278, encryptionId=1099802e804, topicName=老花眼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9d8a96, createdName=doctorzheng, createdTime=Fri Dec 29 15:15:00 CST 2017, time=2017-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541306, encodeId=f3c3154130656, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Sat Dec 09 15:15:00 CST 2017, time=2017-12-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267784, encodeId=03da26e784bc, content=学习了.涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Fri Dec 08 09:02:19 CST 2017, time=2017-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=267777, encodeId=971c26e777a8, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo5nmIH5IQqCKjJgSCuicPWUWOUcdqt1ROPnEiaOYN4pSHibDv8la3OxNLalvuvUXn8clpJlrpuyTpckgt9OPkeSSdT/0, createdBy=8fd71930726, createdName=半夏微凉, createdTime=Fri Dec 08 08:58:39 CST 2017, time=2017-12-08, status=1, ipAttribution=)]
    2017-12-08 半夏微凉

    学习了.谢谢分享

    0

相关资讯

Arch Soc Esp Oftalmol.：基于非镜片矫正老花眼的的手术技术

虽然没有一项技术能够完全消除近视眼镜的需求，但其中许多技术可以改善患者的屈光状态。需要采用严格的标准化方法和较长的随访进行更多的研究来评估患者近视力的变化，以确认其中许多技术的实际和实用性。

Sensors (Basel).：老花眼的新型激光屈光手术治疗：基于光学定制的临床成果的改善

瑞士巴塞尔大学眼科系Studer H教授及其工作团队最近在Sensors (Basel).上发表了他们的最新研究成果：基于光学定制的新型激光屈光手术治疗可以改善老花眼的临床治疗效果。激光辅助原位角膜磨镶术（LASIK）是经过验证的、适于角膜屈光手术的治疗方法。但此项治疗技术会诱发高阶光学畸变，这也是为什么该方法很少用于治疗老花眼（老年相关近视力丧失）的主要原因。在Studer H教授最近的这项研究